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We have shown previously that serum insulin-like growth factor binding protein-3 (IGFBP-3) levels have good predictive value for complete, but not partial, growth hormone deficiency (GHD). In this study, we compare IGFBP-3 levels in short children previously divided into groups on 10 \g=m\g/l. Partial GHD and normal children with short stature also were divided into either low IGF-I or normal IGF-I subgroups. The clinical sensitivity of IGFBP-3 for complete GHD was 92%, whereas its sensitivity for partial GHD was 39%. For partial GHD, among those with low IGF-I (N = 19) 68% were also low for IGFBP-3, while 80% of those with normal IGF-I (N = 30) were also normal for The clinical specificity of IGFBP-3 for normal children with short stature was 69%. For these groups, among those with low IGF-I (N = 22) 73% also were low for IGFBP-3, while 80% of those with normal IGF-I (N = 81) also were normal for . In addition, we tested whether IGFBP-3 can predict the response to GH treatment in prepubertal children by comparing pretreatment with the height gain achieved by 1 (15) . About 70% of these 262 subjects were used to determine normal IGFBP-3 levels. Previously we had determined the low cut-off levels of IGF-I at the ages of 8 and 9 years, separately in males and females (male 140 /¿g/1, female 160/¿g/1) (15) . However, as there was no significant difference in IGF-I level between males and females, we set a single low cut-off level at the ages of 8 and 9 years for both males and females, based on the 5th percentile at those ages (150µg/l). In other age groups, we used the 5th percentile as the low cut-off level; these were the same as in our previous study (15) . The distribution of normal IGF-I levels in our study was not log-normal at all ages, as reported by Blum et al. (18) . This difference is probably due to the small numbers of our normal subjects.
As reported previously (19) , IGFBP-3 measurements were made by the method of Blum and Ranke (16) with a few minor modifications. We added aprotinin (5xl05U/l) and (20) . Height data, except incremental height gain, are shown as sd scores and are based on previously reported height data in Japan (21). Among these prepubertal subjects, the height sd score also was significantly lower in CGHD than in NS children Children with the lowest endogenous GH levels respond most favorably to GH treatment (20 (10/19) and PGHD patients with normal IGF-I (6/10) responded well to treatment. Incremental height gain for the entire group correlated significantly with the pretreatment IGFBP-3 sd score (Fig. 2: r (1) (2) (3) (4) (5) (6) (7) (8) .
The significant correlation between the pretreatment IGFBP-3 sd score and incremental height gain in our prepubertal subjects, including NS children, suggest that IGFBP-3 may reflect endogenous GH status more accurately than do simulation tests if it is true that children with the lowest endogenous GH levels respond most favorably to GH treatment (20 
